STUDY OF SOME ANTIHYPERTENSION DRUGS USE IN CLINICAL PRACTICE
https://doi.org/10.15829/1728-8800-2015-3-70-74
Abstract
The review provides the opinions of scientists on the results of pharmaco- economy analysis of antihypertension drugs usage in different countries. The necessity underlined for the concentration of attention on analytic approach and financing of the State sector of healthcare support on the availability of treatment and prevention of the main chronic diseases. The parameters of economic assessment of efficacy of different antihypertension drugs are not only the criterial for rational usage of restricted resources of healthcare system, but also help to choose the exact drug in clinical situation to provide to the patient the best life quality with real economic wealth.
About the Authors
N. A. Konyshko
SBEI HPE Smolensk State Medical Academy of the Healthcare Ministry. Smolensk, Russia
Russian Federation
Russian Federation
T. E. Morozova
SBEI HPE First Moscow State Medical University n.a. I. M. Sechenov of the Healthcare Ministry. Moscow, Russia
Russian Federation
Russian Federation
References
1. Markelov MU. Marketing analysis of the market of hypotensive drugs// Information technologies in medical and educational research: Materials of inter-regional scientifically-practical conference. Kursk 2008; 2: 26-7. Russian (Маркелов М. Ю. Маркетинговый анализ рынка гипотензивных препаратов. Информационные технологии в медицинских и педагогических исследованиях: Материалы межрегиональной научно-практической конференции. Курск 2008; Ч.2: 26-7).
2. Ostroumova OD, Guseva TF. Combination therapy of arterial hypertension. Eurasian Heart J 2013; 1: 19-30. Russian (Остроумова О. Д., Гусева Т. Ф. Комбинированная терапия артериальной гипертензии. Евразийский кардиологический журнал 2013; 1: 19-30).
3. Bras PL, Ricordeau P, Roussille B, Saintoyant V. L'information des medecins generalistes sur le medicament. Report No RM 2007-136 P. Inspection generale des affaires sociales. September. 2007.
4. British National Formulary. BNF51. London: British Medical Association and Royal Pharmaceutical Society of Great Britain. 2006.
5. Guskov V. Condition and Outlook of the pharmaceutical market. leasing.bta.kz/ files/9-farma_main.pdf. Russian (Гуськов В. Состояние и прогноз фармацевтического рынка/ BTA аналитика [Электронный ресурс]. 2008. Режим доступа: leasing.bta.kz/files/9-farma_main.pdf. Дата доступа 15.05.2010.
6. Varpahovskaya I. Cardiovascular drugs on the world and Russian markets (part I). Remedium 2000; 10: 74-80. Russian (Варпаховская И. Сердечно-сосудистые препараты на мировом и российском рынках (часть I). Ремедиум 2000; 10: 74-80).
7. Duarte JH. Hypertension: Cost-effectiveness of 2014 guidelines. Nat Rev Cardiol 2015; 12 (4): 194.
8. Andreeva GF. Assessment of the level of awareness about the disease of patients with stable arterial hypertension. RFC 2005; 1: 9-12. Russian (Андреева Г. Ф. Оценка уровня информированности о своем заболевании больных со стабильной артериальной гипертензией. РФК 2005; 1: 9-12.
9. Korennova OU. Evaluation of clinical and economical efficacy of combination antihypertensive therapy. Russ J Cardiol 2004; 5: 34-8. Russian (Кореннова О. Ю. Оценка клинико-экономической эффективности комбинированной антигипертензивной терапии. Российский кардиологический журнал 2004; 5: 34-8).
10. Spurling GK, Mansfield PR, Montgomery BD. Information from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians' Prescribing: A Systematic Review. PLoS Med 2010; 7(10): 1000352.
11. Spurling GK. Information from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians' Prescribing: A Systematic Review. PLoS Med 2010; Vol. 19;7(10): 216 c.
12. Gavrilenko LN. The first results of pharmacoepidemiological — sky research "drugs and pregnancy". Materials of scientific-practical conference " the National standard of pharmacology in the Republic of Belarus of 25 years". Minsk 2010; 37-40. Russian (Гавриленко Л. Н. Первые результаты фармакоэпидемиологического исследо¬вания "лекарственные средства и беременность". Материалы научно-практической конференции "Клинической фармакологии в Республике Беларусь 25 лет". Минск 2010; 37-40).
13. Tkachova ON. Actual questions of pathogenesis, diagnosis and treatment of arterial hypertension in pregnant women. M: AGRI 2006; 140 p. Ткачева О. Н. Актуальные вопросы патогенеза, диагностики и фармакотерапии артериальной гипертонии у беременных. М.: АГРИ 2006; 140 с).
14. Huynh L, McCoy M, Law A. Systematic literature review of the costs of pregnancy in the US// Pharmacoeconomics 2013; 31(11): 1005-30.
15. Othman N, Vitry A, Roughead EE. Quality of pharmaceutical advertisements in medical journals: a systematic review. PLoS One 2009; 4: 6350.
16. Liskovich VA. Some questions assignments pharmacological agents in pregnant women with high blood pressure. Reproductive Health 2010; 6: 23-5. Russian (Лискович В. А. Некоторые вопросы назначений фармакологических средств у беременных женщин с повышенным артериальным давлением. Репродуктивное здоровье 2010; 6: 23-5).
17. Oganov RG, Kulakov VI, Tkachova ON. DIALOG, a Multicenter epidemiological study of approaches to the treatment and diagnosis of pregnancy-induced hypertension in Russia. Arterial'naja gipertenzija 2008; 14(1): 27-39. Russian (Оганов Р. Г., Кулаков В. И., Ткачева О. Н. Многоцентровое эпидемиологического исследование "Лечебно-диагностическая тактика ведения беременных с артериальной гипертонией в России "ДИАЛОГ"". Артериальная гипертензия 2008; 14(1): 27-39).
18. Shehtman MM. Diseases of the respiratory and circulatory pregnant. M: Triada-S 2002; 232 p. Russian (Шехтман М.М. Болезни органов дыхания и кровообращения у беременных. М.: Триада-Х 2002; 232 с).
19. Maclure M. Measuring prescribing improvements in pragmatic trials of educational tools for general practi tioners. Basic Clin Pharmacol Toxicol 2006; 98(3): 243-52).
20. The Anatomical Therapeutic Chemical Classification System with Defined Daily Doses (ATC/DDD). WHO Collaborating Centre for Drug Statistics Methodology. Oslo, 2003.
21. Szucs TD, Burnier M, Erne P. Cost-effectiveness of losartan versus atenolol in treating hypertension — an analysis of the LIFE study from a Swiss perspective. Cardiovasc Drugs Ther 2004; 18(5): 391-7.
22. Department of Health. A first class service: quality in the new NHS. London: DOH; 1998.http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH_4006902
23. Venkataraman S, Stremersch S. The debate on influencing doctors' decisions: are drug characteristics the missing link? Manage Sci 2007; 53: 1688-701.
24. Verbeke F1, Lindley E, Van Bortel L, et al. A European Renal Best Practice (ERBP) position statement on the Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Blood Pressure in Non-dialysis- dependent Chronic Kidney Disease: an endorsement with some caveats for real-life application. Nephrol Dial Transplant 2014; 29(3): 490-6.
25. Higgins J. Assessing risk of bias in included studies. In: Altman DG, Higgins JPT, G S, editors. Cochrane handbook for systematic reviews of interventions Version 501 The Cochrane Collaboration. Chichester, UK: Wiley-Blackwell 2008.
26. Heyman SN, Ben Yehuda A, Brezis M. Additional remedies for the failing departments of internal medicine. Harefuah 2010; 149(12): 756-7.
27. de Bakker DH, Coffie DS, Heerdink ER, et al. Determinants of the range of drugs prescribed in general practice: a cross-sectional analysis. BMC Health Serv Res 2007;7:132.
Review
For citations:
Konyshko N.A., Morozova T.E. STUDY OF SOME ANTIHYPERTENSION DRUGS USE IN CLINICAL PRACTICE. Cardiovascular Therapy and Prevention. 2015;14(3):70-74. (In Russ.) https://doi.org/10.15829/1728-8800-2015-3-70-74
Views:
758
Email this article 
